Current partner codePEPTIDESDE
NCT07318467·Not applicable·INTERVENTIONAL

Prophylactic Regimen of Intravenous Oxytocin, Intravenous Tranexamic Acid, and Intramuscular Ergot Derivative for Primary Prevention of Postpartum Hemorrhage in Intrapartum Cesarean Section Versus Intravenous Carbetocin Alone

Status

Not yet recruiting

Phase

Not applicable

Enrollment

80

Locations

0

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

While Carbetocin is effective in reducing PPH, the combination of oxytocin, Tranexamic acid, and Ergot derivatives may offer additional benefits in high-risk populations. We hypothesize that the combination regimen will reduce PPH incidence and severity compared to Carbetocin alone and may be more cost effective

Interventions

Treatment arms and agents.

DRUG

Intravenous Oxytocin, Intravenous Tranexamic Acid, and Intramuscular Ergot Derivative

Group A will receive a combination regimen of intravenous Oxytocin (5-10IU), Tranexamic acid (intravenous bolus 1 gram), and intramuscular ergot derivative (methylergometrine maleate 0.2 mg/ ml). The participants will receive intravenous Oxytocin immediately after delivery of the fetus, intravenous Tranexamic acid during the procedure and intramuscular Ergot derivative after delivery of the placenta

DRUG

Intravenous Carbetocin alone

Group B will receive intravenous Carbetocin (100 mcg) only. The participants will receive intravenous Carbetocin only immediately after delivery of the fetus.

Timeline

From registration to results.

  1. First posted

    Jan 6, 2026

  2. Study start

    Jan 1, 2026

  3. Primary completion

    Jun 30, 2026

  4. Study completion

    Jun 30, 2026

  5. Results posted

    Not reported

  6. Registry updated

    Jan 6, 2026

Outcomes

What the study measures.

Primary outcomes

Amount of blood loss

Time frame · during and up to 24 hours after cesarean section

Secondary outcomes

Not reported in the indexed record.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
45 Years
Sex
FEMALE
Healthy volunteers
Yes

Inclusion Criteria: * Women undergoing C-Sections. * Women between the ages of 18 and 45 years. * Singleton pregnancy. * Gestational age is equal to or more than 36 weeks. * No known coagulopathy or bleeding disorders. * No known hypersensitivity or allergy to drugs used in the study. * Normal obstetric ultrasonography with no fetal abnormalities. Exclusion Criteria: * Hemodynamically unstable or immobile patients. * Multifetal pregnancy. * Patients who are receiving prophylactic or therapeutic anticoagulation. * Known comorbidities and contraindications to the use of Ergot derivatives or Carbetocin such as hypertension or cardiovascular disorders. * Placenta previa and/or Placenta accreta spectrum. * History of thromboembolism. * Preeclampsia or eclampsia. * Any additional measurements needed to control or stop excessive bleeding intraoperatively such as uterine artery ligation or use of sterile gelatin absorbable foam.

Study locations

0 registered sites.

No country data reported. Showing up to 24 locations stored in the fast local snapshot.

No study locations reported.

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Carbetocin.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.